Specify a stock or a cryptocurrency in the search bar to get a summary
Vericel Corporation
ATQPVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Address: 64 Sidney Street, Cambridge, MA, United States, 02139
Analytics
WallStreet Target Price
58.65 EURP/E ratio
4620Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ATQP
Dividend Analytics ATQP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATQP
Stock Valuation ATQP
Financials ATQP
Results | 2019 | Dynamics |